CONTEXT: Researchers conducted extensive investigations of hallucinogens in the 1950s and 1960s. By the early 1970s, however, political and cultural pressures forced the cessation of all projects. This investigation reexamines a potentially promising clinical application of hallucinogens in the treatment of anxiety reactive to advanced-stage cancer. OBJECTIVE: To explore the safety and efficacy of psilocybin in patients with advanced-stage cancer and reactive anxiety. DESIGN: A double-blind, placebo-controlled study of patients with advanced-stage cancer and anxiety, with subjects acting as their own control, using a moderate dose (0.2 mg/kg) ofpsilocybin. SETTING: A clinical research unit within a large public sector academic medical center. PARTICIPANTS: Twelve adults with advanced-stage cancer and anxiety. MAIN OUTCOME MEASURES: In addition to monitoring safety and subjective experience before and during experimental treatment sessions, follow-up data including results from the Beck Depression Inventory, Profile of Mood States, and State-Trait Anxiety Inventory were collected unblinded for 6 months after treatment. RESULTS:Safe physiological and psychological responses were documented during treatment sessions. There were no clinically significant adverse events with psilocybin. The State-Trait Anxiety Inventory trait anxiety subscale demonstrated a significant reduction in anxiety at 1 and 3 months after treatment. The Beck Depression Inventory revealed an improvement of mood that reached significance at 6 months; the Profile of Mood States identified mood improvement after treatment with psilocybin that approached but did not reach significance. CONCLUSIONS: This study established the feasibility and safety of administering moderate doses of psilocybin to patients with advanced-stage cancer and anxiety. Some of the data revealed a positive trend toward improved mood and anxiety. These results support the need for more research in this long-neglected field. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00302744.
RCT Entities:
CONTEXT: Researchers conducted extensive investigations of hallucinogens in the 1950s and 1960s. By the early 1970s, however, political and cultural pressures forced the cessation of all projects. This investigation reexamines a potentially promising clinical application of hallucinogens in the treatment of anxiety reactive to advanced-stage cancer. OBJECTIVE: To explore the safety and efficacy of psilocybin in patients with advanced-stage cancer and reactive anxiety. DESIGN: A double-blind, placebo-controlled study of patients with advanced-stage cancer and anxiety, with subjects acting as their own control, using a moderate dose (0.2 mg/kg) of psilocybin. SETTING: A clinical research unit within a large public sector academic medical center. PARTICIPANTS: Twelve adults with advanced-stage cancer and anxiety. MAIN OUTCOME MEASURES: In addition to monitoring safety and subjective experience before and during experimental treatment sessions, follow-up data including results from the Beck Depression Inventory, Profile of Mood States, and State-Trait Anxiety Inventory were collected unblinded for 6 months after treatment. RESULTS: Safe physiological and psychological responses were documented during treatment sessions. There were no clinically significant adverse events with psilocybin. The State-Trait Anxiety Inventory trait anxiety subscale demonstrated a significant reduction in anxiety at 1 and 3 months after treatment. The Beck Depression Inventory revealed an improvement of mood that reached significance at 6 months; the Profile of Mood States identified mood improvement after treatment with psilocybin that approached but did not reach significance. CONCLUSIONS: This study established the feasibility and safety of administering moderate doses of psilocybin to patients with advanced-stage cancer and anxiety. Some of the data revealed a positive trend toward improved mood and anxiety. These results support the need for more research in this long-neglected field. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00302744.
Authors: Gongliang Zhang; Herborg N Ásgeirsdóttir; Sarah J Cohen; Alcira H Munchow; Mercy P Barrera; Robert W Stackman Journal: Neuropharmacology Date: 2012-06-18 Impact factor: 5.250
Authors: Michael Kometer; Thomas Pokorny; Erich Seifritz; Franz X Volleinweider Journal: Psychopharmacology (Berl) Date: 2015-08-01 Impact factor: 4.530
Authors: M Kaelen; F S Barrett; L Roseman; R Lorenz; N Family; M Bolstridge; H V Curran; A Feilding; D J Nutt; R L Carhart-Harris Journal: Psychopharmacology (Berl) Date: 2015-08-11 Impact factor: 4.530
Authors: Farhana Sakloth; Elizabeth Leggett; Megan J Moerke; E Andrew Townsend; Matthew L Banks; S Stevens Negus Journal: Exp Clin Psychopharmacol Date: 2019-01-10 Impact factor: 3.157
Authors: Rafael G Dos Santos; Flávia L Osório; José Alexandre S Crippa; Jordi Riba; Antônio W Zuardi; Jaime E C Hallak Journal: Ther Adv Psychopharmacol Date: 2016-03-18
Authors: Theresa M Carbonaro; Matthew P Bradstreet; Frederick S Barrett; Katherine A MacLean; Robert Jesse; Matthew W Johnson; Roland R Griffiths Journal: J Psychopharmacol Date: 2016-08-30 Impact factor: 4.153
Authors: Joaquim Soler; Matilde Elices; Alba Franquesa; Steven Barker; Pablo Friedlander; Amanda Feilding; Juan C Pascual; Jordi Riba Journal: Psychopharmacology (Berl) Date: 2015-11-27 Impact factor: 4.530